Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Mele

Plastic Surgery Walnut Creek, CA Medical Doctor

NPI 1851388003 CMS profile 356136

130 La Casa Via, Building 2, Suite 206, Walnut Creek, CA 94598

Open in the dashboard

General payments

$9,498

93 records reported · program years 2019–2025

Research payments

$3,750

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,300 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Joseph Mele of Walnut Creek, CA is reported in the CMS Open Payments database as having received $9,498 across 93 general payments and $3,750 in research payments paid to them. Separately, studies naming them as principal investigator received $2,300 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,264 10
2024 General $1,576 12
2023 General $1,620 17
2022 General $928 13
2022 Research $250 1
2021 General $1,434 18
2021 Research $1,250 1
2020 General $315 6
2020 Research $500 1
2019 General $1,360 17
2019 Research $1,750 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Mele
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Joseph Mele were reported at $2,264. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Joseph Mele Plastic Surgery median Middle half National median
2019 $1,360 $371 $122–$1,483 $163
2020 $315 $158 $52–$438 $114
2021 $1,434 $249 $87–$752 $132
2022 $928 $274 $102–$793 $149
2023 $1,620 $299 $113–$891 $160
2024 $1,576 $361 $124–$1,062 $164
2025 $2,264 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $2,751 33 payments
  2. AbbVie, Inc. $2,569 22 payments
  3. TELA Bio, Inc. $1,441 3 payments
  4. Mentor Worldwide LLC $1,298 12 payments
  5. Sientra, Inc. $671 10 payments
  6. RTI Surgical, Inc $177 1 payment
  7. Integra LifeSciences Corporation $144 1 payment
  8. CooperSurgical, Inc. $115 1 payment
  9. Galderma Laboratories, L.P. $115 7 payments
  10. Musculoskeletal Transplant Foundation Inc. $109 1 payment
  11. Other $109 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,404 86 payments
  2. Travel and Lodging $3,093 7 payments
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $3,311 26 payments
  2. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $2,015 22 payments
  3. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $1,834 14 payments
  4. REVOLVE $1,710 13 payments
  5. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $1,441 3 payments
  6. ALLODERM $952 8 payments
  7. MENTOR MemoryGel Resterilizable Gel Sizer $948 9 payments
  8. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $671 10 payments
  9. NATRELLE $322 8 payments
  10. CORTIVA ALLOGRAFT DERMIS $177 1 payment
  11. Other $1,745 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $3,750 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

33

Median for Plastic Surgery: 39

Drug cost

$239

Median for Plastic Surgery: $219

Branded share of claims

39.4%

Median for Plastic Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 20 $128
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $110

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 700 Part D prescribers listed as Plastic Surgery; they describe a distribution and say nothing about conduct.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record